DON in pediatric cerebral malaria, a phase I/IIA dose-escalation safety study: study protocol for a clinical trial 

Abstract Background Despite treatment with highly effective antimalarial drugs, malaria annually claims the lives of over half a million children under 5-years of age in sub-Saharan Africa. Cerebral malaria (CM), defined as Plasmodium falciparum infection with coma, is the severe malaria syndrome wi...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Nginache Nampota-Nkomba, Osward M. Nyirenda, Jane Mallewa, Yamikani Chimalizeni, Nettie Dzabala, Michael P. Fay, Mathangi Gopalakrishnan, Matthew B. Laurens, Nicole F. O’Brien, Louis H. Miller, Susan K. Pierce, Brittany A. Riggle, Douglas G. Postels
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2024-01-01
Serie:	Trials
Soggetti:	6-Diazo-5-oxo-L-norleucine DON Glutamine antagonist Cerebral malaria Malaria Plasmodium falciparum
Accesso online:	https://doi.org/10.1186/s13063-023-07808-w
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!